Literature DB >> 33949509

Synthesis of asymmetrical diaminobis(alkoxo)-bisphenol compounds and their C1-symmetrical mono-ligated titanium(iv) complexes as highly stable highly active antitumor compounds.

Gilad Nahari1, Edit Y Tshuva.   

Abstract

Asymmetrical 2,2'-((ethane-1,2-diylbis((2-hydroxyethyl)azanediyl))bis(methylene))diphenol substituted compounds and their C1-symmetrical diaminobis(phenolato)-bis(alkoxo) titanium(iv) complexes were synthesized, with one symmetrical analogue. X-ray crystallography corroborated tight ligand binding. Different substitutions on the two aromatic rings enabled fine-tuning of the complex properties, giving enhanced solubility, high anticancer activity (IC50 < 4 μM), and significant hydrolytic stability.

Entities:  

Year:  2021        PMID: 33949509      PMCID: PMC8130176          DOI: 10.1039/d1dt00219h

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


Titanium(iv) complexes play a significant role in anticancer chemotherapy, whereby the biofriendly titanium-based compounds serve as safe alternatives to the toxic platinum-based drugs.[1-8] In fact, the thermodynamic hydrolysis product of titanium(iv) complexes, TiO2, is an inert non-toxic supplement in food, drugs, and cosmetics.[8,9] Titanium(iv) compounds that include diketonato and cyclopentadienyl ligands were presented in the 1980s as active against various cancer cell lines;[10-12] nevertheless, they failed clinical trials due to rapid hydrolysis that leads to formation of undefined clusters;[13-20] this behavior has motivated the design of ligands appropriate for stabilizing the titanium(iv) core in biological environments for sufficient periods to demonstrate defined activity, before the safe, yet inactive, TiO2 is formed. Our group has introduced hydrolytically stable anticancer titanium(iv) complexes based on phenolato ligands (Scheme 1).[3,21-28] The first complexes employed the tetradentate diaminobis(phenolato) salan ligand and demonstrated both in vitro and in vivo activity, alongside enhanced stability.[21-24,29,30] Structure–activity studies revealed that the substituents on the aromatic rings affect the cytotoxic activity and hydrolytic stability of the Ti(iv)-salan complexes.[22,29,31,32] Particularly, NO2 substituents diminish the hydrolytic stability whereas ortho halogenation increases it, especially for Cl and Br substitutions, with reduced impact for F substitutions.[29] A subsequent study explored C1-symmetrical Ti(iv)-salan complexes by utilizing different substitutions on the two phenolato moieties; these complexes exhibited improved cytotoxicity for most derivatives relative to the analogous C2-symmetrical Ti(iv)-salan complexes.[33,34] Following studies promoted the hexadentate diaminobis(phenolato)-bis(alkoxo) ligands for the formation of mono-ligated octahedral Ti(iv) complexes with no labile ligands (Scheme 1).[35] PhenolaTi (Scheme 1, right: R = m,p-di-Me) featured high cytotoxicity toward a wide range of cancer cell lines, including those in the NCI-60 panel, alongside high efficacy in in vivo trials, in addition to remarkable hydrolytic stability.[35-37]
Scheme 1

Ti(iv) complexes with bis(phenolato) salan ligand (left), and with bis(phenolato)-bis(alkoxo) ligand (right).

This paper presents C1-symmetrical Ti(iv) complexes, based on asymmetrical diaminobis(phenolato)-bis(alkoxo) ligands. Aiming to fine-tune the complex properties, we developed a stepwise synthetic procedure for development of ligands with different substituted aromatic rings. Highly cytotoxic and hydrolytically stable complexes with enhanced solubility are reported. Four asymmetrical diaminobis(phenolato)-bis(alkoxo) ligands were synthesized: three with one nitrated ring and one bis-halogenated ring (Scheme 2, L1–3,4H4) and one with two differently bis-halogenated rings (Scheme 2, L2,3H4). For comparison, a representative symmetrical o,p-chlorinated ligand was also synthesized (Scheme 2, L2,2H4), joining the symmetrical p-nitrated ligand previously reported (Scheme 2, L4,4H4).[35] The asymmetrical ligands were prepared in 16–44% yields via a two-step procedure: (a) reductive amination of halogenated salicylaldehyde and 2,2′-(ethane-1,2-diylbis(azanediyl))diethanol; (b) substitution reaction between the product and differently substitute benzylbromide (Scheme 2). The symmetrical ligand L2,2H4 was synthesized in 22% yield by a Mannich condensation similarly to published procedures.[35]
Scheme 2

Synthesis of asymmetrical diaminobis(phenolato)-bis(alkoxo) ligands and their Ti(iv) complexes.

The 1H NMR spectra of L1–3,4H4 (Fig. S1–S3†) and L2,3H4, (Fig. S4†) exhibited five and four distinct signals in the aromatic region, respectively, alongside two singlets of the protons in the different benzyl positions, confirming that Cs-symmetrical ligands had formed. Contrary, the spectrum of L2,2H4 featured two aromatic signals and single set of signals in the aliphatic region as expected (Fig. S5†). The ligands were also characterized by HRMS and/or elemental analysis, confirming that the desired compounds had been obtained. Reaction of the hexadentate ligands with Ti(OiPr)4 overnight under inert conditions, followed by decantation of the precipitates from the THF solution yielded the corresponding octahedral Ti(iv) complexes (Scheme 2). The 1H NMR spectra verified formation of the four desired C1-symmetrical products (L1–3,4Ti, L2,3Ti, Fig. S6–S9†) with different signals in the aromatic region similarly to those of the ligands as discussed above, and with distinct signals of AB system couplings for each of the benzylic protons; additionally, a symmetrical complex (L2,2Ti, Fig. S10†), featured only two signals in aromatic region and a corresponding set of aliphatic signals. Further analysis of a representative complex, L2,4Ti, was performed by 1H–13C HSQC NMR (Fig. S11†). The 1H NMR spectrum features up to 0.64 ppm difference in the chemical shifts of aliphatic protons that bind the same carbon. In contrast, protons binding to different but parallel carbons possess indistinguishable difference in chemical shifts. Accordingly, these protons are characterized by a set of multiplets with integration corresponding to two protons. These findings indicate that the spatial arrangement of the ligand around the metal center influence the chemical environment of the aliphatic moiety more than the feature of C1-symmetry; hence, evincing that the overall structure of the Ti(iv) complex is similar to those of the corresponding C2-symmetrical titanium compounds.[35] A representative complex L3,4Ti crystallized from dichloromethane at −30 °C, and the single crystals were analyzed crystallographically. The X-ray structure (Fig. 1) featured a C1-symmetrical Ti(iv) octahedral complex of a single chelating hexadentate ligand, confirming the NMR data. Moreover, the two OAr moieties bound in a cis-configuration, whereas the aliphatic O-donors bound in a trans-configuration, similarly to C2-symmetrical titanium(iv) analogues,[35] supporting the 1H–13C HSQC NMR analysis. In addition, similar bond lengths and angles (Fig. 1) were obtained, with 1.87–1.88 Å for the covalent Ti–O and 2.20–2.24 Å for the coordinative Ti–N bond lengths. Interestingly, both Ti–O and the Ti–N bonds proximate to the nitrated ring were slightly longer than the corresponding bonds to the donors on the halogenated ring side, in accordance with the electron withdrawal nature of the NO2 substituent.
Fig. 1

ORTEP drawing of L3,4Ti with 50% probability ellipsoids; H atoms and solvent were omitted for clarity. Selected bond lengths (Å) and angels (°): Ti(1)–O(1) 1.871(2), Ti(1)–O(2) 1.876(2), Ti(1)–O(3) 1.880(2), Ti(1)–O(4) 1.886(2), Ti(1)–N(1) 2.205(2), Ti(1)–N(2) 2.241(2); O(1)–Ti(1)–O(4) 107.19(7), O(2)–Ti(1)–O(3) 157.76(8), N(1)–Ti(1)–N(2) 81.33(7).

The hydrolytic stability of the complexes was evaluated by 1H NMR, monitoring the signals of the Ti(iv) complexes in DMSO-d6 solution comprising 10% D2O, based on procedures reported previously.[35] Whereas the nitrated/fluorinated complex L1,4Ti demonstrated a moderate hydrolytic stability with t1/2 of 25 h (Table S1†), all other complexes exhibited a high stability with less than 25% hydrolysis following 72 h from D2O addition (Table S1†). These results are notable as the corresponding nitrated C2-symmetrical titanium(iv) complex L4,4Ti was not evaluated due to insufficient solubility.[35] The results are also in agreement with previous reports on the reduced stabilizing effect of fluoro substitution in salan-type complexes.[29] The nitro substituent very slightly decreased the hydrolytic stability of the complex relatively to solely halogenated complexes and to a symmetrical methylated derivative.[35] This observation confirms that the hexadentate bis(phenolato)-bis(alkoxo) ligand binding is the main contributor to the complex stability. The cytotoxic activity of the Ti(iv) complexes was analyzed toward human colon HT-29, human ovarian A2780, and human ovarian cisplatin-resistant A2780cp cancer cell lines. The viability of the cells was measured by the methylthiazolyldiphenyltetrazolium (MTT) assay, as previously published (Fig. 2).[38] All titanium(iv) complexes exhibited a marked cytotoxicity against the analyzed cancer cell lines, with IC50 values <4 μM (Fig. 2), indicating activity higher than that of cisplatin toward HT-29 and A2780cp cells (cisplatin: 13 and 33 μM, respectively).[35] Moreover, the complexes demonstrated high cytotoxic activity against the cisplatin-resistant ovarian A2780cp cancer cells, supporting a different mechanism of action of these titanium compounds than that of platinum drugs.[2,39] Notably, although activity is similar for asymmetrical and symmetrical complexes, the mono-nitrated C1-symmetrical complexes reached somewhat higher maximal inhibition (MI) of HT-29 cell growth (∼67–80%), unlike the 60% MI obtained for the corresponding C2-symmetrical bis-nitrated complex,[35] presumably due to enhanced solubility (with higher MI values for the ovarian lines; Fig. 2). Particularly, L2,4Ti exhibited the highest MI value (80%) compared with those of L1,4Ti (67%) and L3,4Ti (74%), differences that are mostly attributed to different solubilities. In fact, the mono-nitrated complexes exhibited solubility in medium ca. 4-fold higher compared with the corresponding value of the reported bis-nitrated complex.[35] Thus, fine tuning the complex properties yielded higher solubility/lipophilicity, which improved the accessibility of the complex to its cellular target.
Fig. 2

Dependence of HT-29 (top), A2780 (middle), and A2780cp (bottom) cell viability based on the MTT assay following a three day incubation period with administered concentration of LTi; in parenthesis: relative IC50 values (μM), maximal cell growth inhibition (MI) (%).

Conclusions

In conclusion, this paper presents a synthetic procedure for a family of asymmetrical 2,2′-((ethane-1,2-diylbis((2-hydroxyethyl)azanediyl))bis(methylene))diphenol compounds, and their C1-symmetrical Ti(iv) complexes as characterized crystallographically. Such organic and inorganic compounds with wider possibilities of steric and electronic characteristics may be employed for various applications, from catalysis to medicine. Particularly, fine tuning of complex features by incorporation of different substituents on the two aromatic rings identified complexes of enhanced solubility in biologically-relevant environments that are highly stable in the presence of water and highly cytotoxic on colon and ovarian, cisplatin-sensitive and -resistant lines. These results highlight the advantages of the diaminobis(phenolato)-bis(alkoxo) ligand system for the stabilization of titanium(iv) metal centers and expand the opportunities for their use in anticancer therapy, as well as in various other fields.

Author contributions

Gilad Nahari: Conceptualization, methodology, validation, formal analysis, investigation, writing – original draft, writing – review & editing, visualization Edit Y. Tshuva: Conceptualization, resources, writing – review & editing, visualization, supervision, project administration, funding acquisition.

Conflicts of interest

There are no conflicts to declare.
  28 in total

1.  A marked synergistic effect in antitumor activity of salan titanium(IV) complexes bearing two differently substituted aromatic rings.

Authors:  Hagai Glasner; Edit Y Tshuva
Journal:  J Am Chem Soc       Date:  2011-10-04       Impact factor: 15.419

2.  Anticancer metal complexes: synthesis and cytotoxicity evaluation by the MTT assay.

Authors:  Nitzan Ganot; Sigalit Meker; Lilia Reytman; Avia Tzubery; Edit Y Tshuva
Journal:  J Vis Exp       Date:  2013-11-10       Impact factor: 1.355

3.  C1-symmetrical titanium(IV) complexes of salan ligands with differently substituted aromatic rings: enhanced cytotoxic activity.

Authors:  Hagai Glasner; Edit Y Tshuva
Journal:  Inorg Chem       Date:  2014-03-03       Impact factor: 5.165

4.  Specific Design of Titanium(IV) Phenolato Chelates Yields Stable and Accessible, Effective and Selective Anticancer Agents.

Authors:  Sigalit Meker; Ori Braitbard; Matthew D Hall; Jacob Hochman; Edit Y Tshuva
Journal:  Chemistry       Date:  2016-06-20       Impact factor: 5.236

Review 5.  Metal-based anticancer chemotherapeutic agents.

Authors:  Nafees Muhammad; Zijian Guo
Journal:  Curr Opin Chem Biol       Date:  2014-03-05       Impact factor: 8.822

6.  Clinical phase I and pharmacokinetic trial of the new titanium complex budotitane.

Authors:  T Schilling; K B Keppler; M E Heim; G Niebch; H Dietzfelbinger; J Rastetter; A R Hanauske
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

7.  Synthesis, characterization, cytotoxicity, and hydrolytic behavior of C2- and C1-symmetrical Ti(IV) complexes of tetradentate diamine bis(phenolato) ligands: a new class of antitumor agents.

Authors:  Dani Peri; Sigalit Meker; Michal Shavit; Edit Y Tshuva
Journal:  Chemistry       Date:  2009       Impact factor: 5.236

8.  Effective Oral Administration of an Antitumorigenic Nanoformulated Titanium Complex.

Authors:  Gilad Nahari; Ori Braitbard; Liraz Larush; Jacob Hochman; Edit Y Tshuva
Journal:  ChemMedChem       Date:  2020-07-30       Impact factor: 3.466

9.  Titanium Tackles the Endoplasmic Reticulum: A First Genomic Study on a Titanium Anticancer Metallodrug.

Authors:  Maya Miller; Anna Mellul; Maya Braun; Dana Sherill-Rofe; Emiliano Cohen; Zohar Shpilt; Irene Unterman; Ori Braitbard; Jacob Hochman; Edit Y Tshuva; Yuval Tabach
Journal:  iScience       Date:  2020-06-12

10.  Highly Stable Tetra-Phenolato Titanium(IV) Agent Formulated into Nanoparticles Demonstrates Anti-Tumoral Activity and Selectivity.

Authors:  Sigalit Meker; Ori Braitbard; Katrin Margulis-Goshen; Shlomo Magdassi; Jacob Hochman; Edit Y Tshuva
Journal:  Molecules       Date:  2015-10-09       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.